CJM Wealth Advisers Ltd. Has $601,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

CJM Wealth Advisers Ltd. raised its stake in Johnson & Johnson (NYSE:JNJ) by 8.4% during the 1st quarter, Holdings Channel reports. The institutional investor owned 3,797 shares of the company’s stock after purchasing an additional 294 shares during the quarter. CJM Wealth Advisers Ltd.’s holdings in Johnson & Johnson were worth $601,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Keener Financial Planning LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $40,000. WFA Asset Management Corp grew its stake in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in Johnson & Johnson in the 4th quarter valued at $44,000. Disciplined Equity Management Inc. acquired a new position in Johnson & Johnson in the 4th quarter valued at $45,000. Finally, Grayhawk Investment Strategies Inc. grew its stake in Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after buying an additional 259 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on JNJ shares. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Monday. Finally, Bank of America dropped their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Hold” and an average target price of $174.07.

Johnson & Johnson Stock Up 1.5 %

Shares of NYSE:JNJ opened at $147.77 on Friday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The company has a market capitalization of $355.64 billion, a PE ratio of 9.21, a PEG ratio of 2.42 and a beta of 0.53. The company has a 50 day moving average price of $148.02 and a two-hundred day moving average price of $154.45.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same quarter in the prior year, the firm earned $2.68 earnings per share. The business’s quarterly revenue was up 2.3% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.36%. The ex-dividend date of this dividend was Monday, May 20th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.